Rimegepant for Endometriosis
What You Need to Know Before You Apply
What is the purpose of this trial?
The purpose of this study is to evaluate the efficacy of rimegepant 75 mg versus placebo in reducing endometriosis-associated pain (EAP) in women with moderate-to-severe pain and histologically confirmed endometriosis.
Who Is on the Research Team?
Yohannes Woldeamanuel, MD
Principal Investigator
Mayo Clinic
Are You a Good Fit for This Trial?
This trial is for women who have been diagnosed with endometriosis through tissue testing and are experiencing moderate to severe pain from the condition.Inclusion Criteria
Exclusion Criteria
What Are the Treatments Tested in This Trial?
Interventions
- Rimegepant
Trial Overview
The study compares rimegepant (a medication taken at a dose of 75 mg) to a placebo, to see if it helps reduce pain caused by endometriosis. Participants are randomly assigned to either group.
How Is the Trial Designed?
2
Treatment groups
Experimental Treatment
Placebo Group
Participants randomized to this arm will receive Rimegepant 75 mg administered orally every other day for 12 weeks.
Participants randomized to this arm will receive matching placebo capsules administered orally every other day for 12 weeks.
Find a Clinic Near You
Who Is Running the Clinical Trial?
Mayo Clinic
Lead Sponsor
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.